Elotuzumab

EMPLICITI®

Overview

Elotuzumab is a type of drug called a monoclonal antibody that is used in the treatment of multiple myeloma. Elotuzumab targets a protein called SLAMF7, which is found on multiple myeloma cells. 

SparkCures ID 37
Developed By Bristol Myers Squibb
Brand Name Empliciti®
Generic Name Elotuzumab
Additional Names HuLuc63
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refracto...
MAGNETISMM-32
View Trial
Verified
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investi...
MONUMENTAL-6
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Phase 1B / 2 Study of Selinexor in Combination With Other Treatments for Relapsed/Refractory and Newly Diag...
STOMP
View Trial
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapie...
CERVINO
View Trial
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
IMPEDE
View Trial
Safety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- a...
ELOTUZUMAB COMBINATION THERAPY
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refracto...
MAGNETISMM-32
View Trial
Verified
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investi...
MONUMENTAL-6
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Phase 1B / 2 Study of Selinexor in Combination With Other Treatments for Relapsed/Refractory and Newly Diag...
STOMP
View Trial
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapie...
CERVINO
View Trial
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
IMPEDE
View Trial
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
BELANTAMAB MAFODOTIN AND ELOTUZUMAB
View Trial
Safety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- a...
ELOTUZUMAB COMBINATION THERAPY
View Trial
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
ELOTUZUMAB + IBERDOMIDE POST ABECMA
View Trial
Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma
IBERDOMIDE COMBINATION THERAPY
View Trial
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.